Fate Therapeutics Inc FATE:NASDAQ

Last Price$17.61NASDAQ Closing Price as of 3:59PM ET 9/18/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.62(3.65%)
Bid (Size)$17.38 (1)
Ask (Size)$18.00 (1)
Day Low / High$16.95 - 17.80
Volume802.8 K

View Biotechnology IndustryPeer Comparison as of 09/18/2019


Fate Therapeutics Inc ( NASDAQ )

Price: $17.61
Change: +0.62 (3.65%)
Volume: 802.8 K
3:59PM ET 9/18/2019

Editas Medicine Inc ( NASDAQ )

Price: $25.29
Change: -0.47 (1.82%)
Volume: 458.1 K
4:00PM ET 9/18/2019

Veracyte Inc ( NASDAQ )

Price: $25.94
Change: -0.23 (0.88%)
Volume: 404.8 K
3:59PM ET 9/18/2019

Sangamo Therapeutics Inc ( NASDAQ )

Price: $10.78
Change: -0.38 (3.41%)
Volume: 784.7 K
4:00PM ET 9/18/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Read more news Recent News

Fate Therapeutics Closes Stock Offering; Underwriters Boost Gross Proceeds Over $173 Million
4:12PM ET 9/18/2019 MT Newswires

Fate Therapeutics (FATE) slipped 1% in extended trade after the biopharmaceuticals company late Wednesday said underwriters participating in its recent...

Significant Insider buy of Fate Therapeutics (FATE) Shares Reverses Selling Trend of Last Quarter
9:53AM ET 9/18/2019 MT Newswires

One Fate Therapeutics insider -- Redmile Group Llc, 10% Owner and Director -- today, acquired 857,143 shares having a market value of approximately...

Insider Trends: Insider Buying Prolonged with Purchase of Fate Therapeutics Stock
4:24PM ET 9/17/2019 MT Newswires

Redmile Group Llc, 10% Owner and Director, reported a purchase of 857,143 shares of Fate Therapeutics (FATE) on Sep 16, 2019, for $15,000,003. Redmile...

Analyst Actions: Piper Jaffray Cuts Fate Therapeutics PT to $28 From $30, Maintains Overweight Rating
9:31AM ET 9/16/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $25. Price: 17.93, Change: +0.48, Percent Change: +2.75...

Company Profile

Business DescriptionFate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
Address3535 General Atomics Court
San Diego, California 92121
Number of Employees104
Recent SEC Filing09/17/2019SC 13D/A
President, Chief Executive Officer & DirectorJ. Scott Wolchko
Chief Scientific OfficerDaniel D. Shoemaker
Vice President-Clinical DevelopmentYu Waye Chu
Senior Vice President-Corporate DevelopmentJim Beitel

Company Highlights

Price Open$17.29
Previous Close$16.99
52 Week Range$11.00 - 22.82
Market Capitalization$1.2 B
Shares Outstanding65.4 M
SectorHealth Technology
Next Earnings Announcement11/07/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.22
Beta vs. S&P 500N/A
Revenue$4.7 M
Net Profit Margin-934.70%
Return on Equity-50.05%

Analyst Ratings as of 08/08/2019

Consensus RecommendationConsensus Icon
Powered by Factset